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Relationship between HMGB1 content and MHC-II ex-
pression in circulating monocytes and spleen of mice
challenged with zymosan
LÜ Yi吕艺, LU Jiang-yang 陆江阳*, ZHAO Min赵敏, LI Zhi-hong 李志宏 and YANG Yi 杨毅
Objective:    To observe the regularity of change in high
mobility group protein box 1 (HMGB1) content in serum
and spleen of mice with multiple organ dysfunction syn-
drome (MODS),  to analyze the correlation between HMGB1
content and major histocompatibility complex (MHC)-II—
I-Ab expression on monocytes in blood and spleen, and to
explore the effect of HMGB1 on immune function of circu-
lating monocytes and splenocytes.
Methods:    One hundred 8-week-old male 57BL/6 mice
were randomly divided into normal group and experimental
group subdivided into 8 subgroups: 3, 8, 12 hours, 1, 2, 3, 5-
7 days and 10-12 days post zymosan injection (PZI). MODS
model was replicated by injecting zymosan into the perito-
neal cavity. At each time point, blood and spleen were col-
lected to detect HMGB1 content and the rate of I-Ab posi-
tive monocytes.
Results:    In normal and PZI 3-hour, 8-hour mice, serum
HMGB1 was not detected, but it significantly increased at
PZI 12 hours. In spleen of normal mice, there was low level
of HMGB1 expression. In zymosan-treated mice, HMGB1
started to rise in spleen at PZI 3 hours. Subsequently,
HMGB1 content in both serum and spleen significantly
increased, and it reached the peak level in 1-2 days, de-
creased in 5 days, and then increased in 10-12 days. The num-
ber of I-Ab positive monocytes in circulating blood and
spleen decreased at 1-2 days (t=9.589, 4.432, P<0.01) and
10-12 days following the challenge, forming a two trough
like decrease, just corresponding with two-peak increase of
HMGB1. However, at 3 hours after zymosan challenge, I-Ab ex-
pression on circulating monocytes was downregulated (t=5.977,
P<0.01), while that in spleen upregulated (t=4.814, P<0.01).
Conclusion:    In mice with MODS, up-regulated
HMGB1expression can regulate I-Ab expression on monocytes
to depress their ability of presenting antigen, which results in
immune disturbance contributing development of MODS.
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Multiple organ dysfunction syndrome (MODS)is a complication with high mortality in pa-tients with severe trauma or burns, and also
the end phase of sepsis.1 The major pathogenesis is
considered to be overwhelming inflammation induced
by immune imbalance. Recently, it was discovered that
high mobility group box 1 protein (HMGB1) is involved
in participating in the expression and synthesis of in-
flammatory cytokines,2 and possesses some charac-
teristics of inflammatory mediators itself.3 HMGB1 is
related to the pathogenesis of autoimmune disease.4, 5
It may be deduced that HMGB1 may participate in the
development of some diseases by interfering with im-
mune function.
Monocytes are important cells with immunocom-
petence. Its antigen presentation property is associ-
ated with major histocompatibility complex (MHC) II. It
plays a role in pathophysiology of sepsis in that they
take part in both the initial inflammatory responses and
the secondary immunodepression.6 Spleen is the larg-
est organ of reticulate-endothelial system in human,
and it plays a crucial role in modulating immuno-
reactions.
The present study was designed to replicate MODS
model by injecting zymosan into the peritoneal cavity
of mice, and then to observe change in HMGB1 con-
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tent and MHC-II expression on monocytes in the pe-
ripheral blood and spleen, and the relationship between
them, and to explore the effect of HMGB1 on immunity
and the pathogenesis of MODS.
METHODS
Animal model7
A total of 100 male 57BL/6 mice, 8-week-old, each
weighing 20-25 g, were purchased from the experimen-
tal animal center of Army Institute of Medical Sciences,
China. The animals were allowed to acclimate for 7 days
before use in the animal laboratory under the standard
temperature and 12-12 hours’ light-dark cycle. The mice
were allowed to have access to water ad labium, but
food was withdrawn for 12 hours before the experiment.
The mice were randomly divided into normal and ex-
perimental groups with 8 subgroups which included 3,
8, 12 hours, 1 , 2 , 3, 5-7 and 10-12 days post zymo-
san injection (PZI, n=10 for each group). MODS model
was replicated by injecting zymosan (Sigma, USA) into
the abdominal cavity (1 g/kg body weight, suspended
in paraffin oil).
The experimental protocol was approved by the
Experiment Committee of 304th Hospital Affiliated to
the PLA General Hospital.
SDS-PAGE gel electrophoresis and Western blot
analysis for HMGB1 content in serum and spleen
SDS-PAGE and Western blot analysis of HMGB1
were performed as data described.8 Briefly, sera
samples were diluted 4:1 with 5×sample buffer (250
mmol Tris-HC l, pH 8.6, 500 mmol DTT, 10% SDS, 0.5%
bromophenol blue, 50% glycerol). Spleen was homog-
enized with PBS, and it was placed in ice bath for 30
minutes, and then centrifuged at 2000×g, at the tem-
perature of 4°C for 30 minutes. The supernatant was
mixed with an equal volume of  5×sample buffer. The
diluted samples of serum and spleen homogenate were
heated at 100°C for 5 minutes and spun down at 10 000×g,
4°C, for 5 minutes. The supernatants were loaded and
subjected to electrophoresis through 12% SDS-PAGE
gel and electrotransferred onto a polyvinylidene difluoride
membrane, and probed with anti-HMGB1 polyclonal
rabbit antiboty (BD Pharmingen, USA) at 1:3000 and
HRP-conjugated goat anti-rabbit IgG at 1:2000
(Zhongshan Jinqiao Company, Beijing, China) for Western
blot analysis. Membranes were developed with chemi-
luminescent kit (Pierce, USA) and exposed to film.
Flow cytometer for I-Ab labeled monocytes
A total of 100 µl blood was collected from orbital
vein of mice, heparinized, incubated with 5 µl FITC-con-
jugated rat antibody against mice I-Ab (Serotec,USA)
in darkness at room temperature for 30 minutes. Red
blood cells were lysed, and the monocytes were washed
with PBS, then the cells were fixed with 4% paraform-
aldehyde in PBS, and the rate of I-Ab positive mono-
cytes was analyzed on a FACScalibur flow cytometer
(Becton Dickinson, USA).
Spleen HMGB1 and I-Ab detection by immu-
nochemistry
Formalin-fixed, paraffin-embedded spleen tissues
from mice were cut into 4 µm sections. HMGB1 was
detected with a three-step immunostaining procedure
using the primary rabbit anti-mouse antibody (1:300,
BD Pharmingen, USA).
At the end of all time points, the spleen tissues
were embedded with OCT and frozen, then were cut
into 5 µm sections. Each section was mounted on a
glass slide. The primary antibody (concentration 1:100
in PBS) was rat anti-mouse I-Ab polyclonal antibody
(Serotec,USA). Immunocomplexes were detected with
a Two-Step IHC Detection Reagent according to the kit
instruction (Zhongshan Jinqiao Company, Beijing,
China). The sl ides were counterstained with
hematoxylin. Ten visual fields were randomly selected
from each slide, and all positive cells and total cells of
each visual field were counted. Data were shown as
percentage of I-Ab positive cells.
Statistical analysis
Data were expressed as mean±SD, and analyzed
by Stata 7.0 software. The statistical significance be-
tween groups was assessed using unpaired Student’s
t test. P<0.05 was considered statistically significant.
RESULTS
Time course of multiple organ dysfunction induced
by zymosan injection in mice
The injection of zymosan into peritoneal cavity
caused a typical biphasic pathophysiological course.
The “first hit” was at 12-48 hours PZI, and the mice
showed acute inflammatory injury, featured by over-
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whelming/uncontrolled inflammation, and then the state
of illness showed a remission at 5-7 days postinjury;
the second insult occurred at 10-12 days after zymo-
san injection, and the mice manifested  functional fail-
ure and structural damage of multiple organs.7
Change in HMGB1 content in serum and spleen
In normal and PZI 3-hour, 8-hour mice, there was
no HMGB1 detected in serum. At PZI 12 hours, the
serum HMGB1 content was significantly increased, and
it reached a much higher level in PZI 1 day serum, and
then gradually decreased. On PZI 5 days, serum
HMGB1 was not detectable, but it was markedly high
again on PZI 10 days (Fig. 1).
In spleen of normal mice, there was a low level of
HMGB1 expression. In zymosan-treated mice,  HMGB1
started to rise at PZI 3 hours, and it increased further at
PZI 8 hours, peaking on PZI 2 days. Subsequently, it
showed a tendency to lower, approaching normal level
on PZI 5-7 days. At PZI 10 days, HMGB1 was increased
again. The regularity of change in HMGB1 content in
spleen was almost consistent with that in serum.
Immunochemical staining of spleen tissue showed
that the rate of HMGB1 positive cells was 6.58% in
normal mice, and it rose to 42.55% after PZI 8 hours,
decreased to 11.8%-8.45% during PZI 12-24 hours, and
peaked to 83.64% at PZI 48 hours, came down on PZI
5 days, but slightly increased on PZI 10 days (17.21%).
Changes in MHC-II expression on monocytes in
blood and spleen
The extent of I-Ab expression on monocytes in blood
and spleen was shown in Fig.2. Both of them changed
according to the severity of the illness. In normal mice,
the rate of monocytes with positive I-Ab expression in
blood was above 30%, and it was markedly lowered at
PZI 3 hours (t=5.977, P<0.01). There were two low val-
ues presented on PZI 2 days (t=9.589, P<0.01) and 10
days, and it reached the lowest on 10 days among all time
points, only about one-third of the normal value (t=10.309,
P<0.01, Fig. 2).
In the spleen, there was a prominent increase in I-Ab
positive cells at PZI 3 hours (t=4.814, P<0.01). But at
PZI 2 days and 10 days, there were less I-Ab positive
cells (t=4.432, 7.955, P<0.01), which was in accor-
dance with the change in the number of monocytes
DISCUSSION
MODS is a cumulative consequence of progressive
deterioration of function occurring in several organ
systems, frequently observed after septic shock, mul-
tiple trauma, severe burns, or pancreatitis.9,10 Injection
of zymosan into the peritoneal cavity can induce acute
peritonitis, which may develop delayed and uncontrolled
inflammation and result finally in functional and struc-
tural injuries of multiple organs, i.e. MODS. The zymo-
san-induced MODS model 7, 11 replicated well the “two-
hit” developing process of clinical MODS: the first phase
takes place at 12-72 hours after administration of
zymosan, and the animals mainly manifest systemic
inflammatory response syndrome (SIRS) developed
from overwhelming inflammation; the second phase is
on 10-12 days after injection of zymosan, and the in-
jured animals present multiple organ failure and mani-
fest immunosuppression.
HMGB1 is an abundant, highly conserved cellular
protein that binds to DNA and stabilizes nucleosome
formation, facilitates gene transcription, and regulates
the activity of steroid hormone receptors.12, 13, 14 The ex-
tracellular role of HMGB1 in inflammation and sepsis
was first described by Wang, et al. HMGB1 was iden-
tified as a late mediator of sepsis, as the serum con-
centration of HMGB1 significantly increased 16 to 32
hours after LPS administration in mice.2 HMGB1 par-
ticipates in the pathogenesis of systemic inflammation
expressing I-Ab in the blood.
Fig. 1.  Change of HMGB1 content in blood and spleen.
Fig. 2.  Rate of positively stained monocytes for I-Ab in blood and
spleen. *P<0.01 (compared with normal group): #P<0.01
(compared with 5 d PZI).
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after the early mediator response has resolved. Extra-
cellular HMGB1 can be released by cells undergoing a
necrotic cell death pathway.15 In addition to responding
to passively released HMGB1, activated monocytes and
macrophages, dendritic cells and NK cell clones can
secrete HMGB1 actively in response to various stimuli
like LPS, pro-inflammatory cytokines and so on.16,17
Secreted HMGB1 in turn triggers the release of several
cytokines from monocytes as well as neutrophils.3, 18 In
this way, HMGB1 behaves as a cytokine. As HMGB1
can stimulate the release of HMGB1 from the same
cells it activates, it can start a positive-feedback
autocrine or paracrine loop that maintains the inflam-
matory cascade.
Much attention has been paid to the effect of HMGB1
in blood in the pathogenesis of  sepsis or other inflam-
matory syndromes,5,19 and the relationship between the
development of illness and the change in HMGB1 ex-
pression and distribution in organs and tissues has been
neglected. Our study found that administration of zy-
mosan could cause an increase in HMGB1 content in
both serum and spleen. HMGB1 content reached the
highest level in 1-2 days, and then decreased in 5 days,
increased again in 10-12 days. Changes in HMGB1
content in serum and spleen were associated with the
severity and remission of illness.7 The time points of
increase in HMGB1 content were in accordance with
the time of high death rate of zymosan-treated mice.
The first peak of HMB1 content corresponded well with
the rapid developing period of systemic inflammation
and multiple organ dysfunction. The second peak of
HMGB1 corresponded with the phase of immunosup-
pression and multiple organ failure, and with deteriora-
tion of the mice. On the other hand, the general state of
the mice gradually recovered with accompanying de-
crease in HMGB1 content in blood and spleen.
Therefore, it is apparent that there is a strong correla-
tion between the HMGB1 content and the course of
sepsis and development of MODS. However, the time
point of change in HMGB1 content was different be-
tween serum and spleen. Serum HMGB1 was not de-
tectable until 12 hours after zymosan challenge. But in
spleen, the amount of HMGB1 expression was less in
normal mice. HMGB1 content started to increase at 3
hours after zymosan challenge, and it was earlier than
that in serum. This phenomenon suggested that the
increased HMGB1 in serum not only came from active
secretion by activated monocyte/macrophage, but also
from passive release by damaged and necrotic cells. 20,21
HMGB1 has been shown to mediate inflammation, to
regulate the migration of monocytes, to activate many
inflammatory cells including monocytes, neutrophils and
endothelium, and also to contribute to dendritic cells
maturation and induction of immune responses.22, 23
HMGB1 is a potent macrophage/monocyte activator. It
can lead to increased production of TNF, IL-1, and other
proinflammatory mediators, which induce systemic in-
flammation and sepsis, and mediate organs dysfunc-
tion and disturbance of immunity.18, 24
The present study revealed that HMGB1 originated
from organs may play a regulating role early by way of
autocrine and paracrine, thus inducing pathophysiologic
changes earlier than HMGB1 released from blood cells.
Therefore, the strategy of inhibiting expression and re-
lease of HMGB1 should be executed before the ap-
pearance of HMGB1 in blood.
The profound immunological dysfunction is an im-
portant lethal mechanism in sepsis and MODS.1 I-Ab
on monocyte, as a major MHC-II in mice, is essential
in presenting bacterial antigen to CD4
+ lymphocytes.
Low MHC-II expression on antigen present cells (APC)
affects activation and immune response of T cell, and it
is a crucial factor inducing immunosuppression.25 MHC-II
is mainly expressed on the surface of immunocytes
including dendritic cells, matured B cells, activated T
cells and monocyte/macrophage, with a property of pre-
senting antigen. In this study, we observed that there
was a correlation between the level of I-Ab expression
and HMGB1 in circulating monocytes and splenocytes
in the development of MODS. At 3 hours after zymosan
challenge, both I-Ab expression and HMGB1 content
were increased in spleen, and I-Ab  expression on circu-
lating monocytes was reduced, but no HMGB1 was
detectable in the blood. But in 2, 5 and 10 days after
the challenge, change in I-Ab expression presented an
opposite tendency of change in HMGB1 content, and it
was consistent with the development of sepsis, as shown
as an increase in HMGB1 content accompanied with a
decrease in I-Ab expression and deterioration of sepsis.
The results suggest that at the early stage of zymosan
challenge, there is a depression of ability of antigen
presentation of circulating monocytes, while that of
splenocytes are excessive, indicating that there is an
imbalance of immune response between immune or-
gan and peripheral immunocytes. It also reveals that
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HMGB1 influences the prognosis of MODS by interfer-
ing MHC-II expression and cell-mediated immunity.
In summary, in the development of zymosan induced
MODS in mice, the level of MHC-II expressed on mono-
cytes correlates with change in HMGB1 content and
the severity of illness. Therefore, strategies to interfere
excessive expression, release or secretion of HMGB1
may be beneficial in maintaining a balance in immune
response, thus preventing the development of MODS.
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